Teladoc Health, Inc. (NYSE:TDOC) Short Interest Down 19.0% in March

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 21,720,000 shares, a drop of 19.0% from the March 15th total of 26,820,000 shares. Currently, 12.7% of the company's stock are sold short. Based on an average trading volume of 7,660,000 shares, the short-interest ratio is presently 2.8 days.

Teladoc Health Stock Down 1.0 %

Shares of TDOC traded down $0.07 during mid-day trading on Friday, reaching $7.19. The company's stock had a trading volume of 2,388,172 shares, compared to its average volume of 6,225,181. Teladoc Health has a 1 year low of $6.35 and a 1 year high of $15.21. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -1.25 and a beta of 1.73. The business has a fifty day moving average of $8.52 and a 200 day moving average of $9.57.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The business had revenue of $640.49 million for the quarter, compared to analysts' expectations of $639.44 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. As a group, analysts forecast that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Adam C. Vandervoort sold 11,011 shares of Teladoc Health stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $8.42, for a total value of $92,712.62. Following the completion of the transaction, the insider now owns 64,308 shares in the company, valued at approximately $541,473.36. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.58% of the stock is owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Golden State Wealth Management LLC boosted its position in Teladoc Health by 102.6% during the first quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider's stock valued at $27,000 after purchasing an additional 1,690 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Teladoc Health by 313.8% during the 4th quarter. Versant Capital Management Inc now owns 3,219 shares of the health services provider's stock valued at $29,000 after buying an additional 2,441 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in shares of Teladoc Health in the 4th quarter valued at approximately $29,000. Lindbrook Capital LLC increased its holdings in Teladoc Health by 78.9% in the fourth quarter. Lindbrook Capital LLC now owns 3,654 shares of the health services provider's stock worth $33,000 after buying an additional 1,612 shares during the last quarter. Finally, Sterling Capital Management LLC raised its position in Teladoc Health by 776.7% during the fourth quarter. Sterling Capital Management LLC now owns 4,629 shares of the health services provider's stock valued at $42,000 after acquiring an additional 4,101 shares in the last quarter. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TDOC. Piper Sandler dropped their price objective on shares of Teladoc Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Royal Bank of Canada raised their target price on Teladoc Health from $11.00 to $12.00 and gave the company an "outperform" rating in a research note on Friday, January 24th. Needham & Company LLC reiterated a "hold" rating on shares of Teladoc Health in a research report on Thursday, February 27th. The Goldman Sachs Group decreased their target price on shares of Teladoc Health from $16.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, Citigroup cut their price target on Teladoc Health from $11.00 to $8.75 and set a "neutral" rating on the stock in a report on Friday. Twelve investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $10.71.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.